IP Verse

Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect - EP3368071

The patent EP3368071 was granted to Revance Therapeutics on Jan 26, 2022. The application was originally filed on Oct 28, 2016 under application number EP16860952A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3368071

REVANCE THERAPEUTICS
Application Number
EP16860952A
Filing Date
Oct 28, 2016
Status
Granted And Under Opposition
Dec 24, 2021
Grant Date
Jan 26, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

IPSEN BIOPHARMAOct 26, 2022MATHYS & SQUIREADMISSIBLE

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP1514556
DESCRIPTIONUS2010330123
DESCRIPTIONUS2011268765
DESCRIPTIONUS2013251770
DESCRIPTIONUS5877278
DESCRIPTIONUS6444209
INTERNATIONAL-SEARCH-REPORTUS2002028765
INTERNATIONAL-SEARCH-REPORTUS2011268765
OPPOSITIONEP1817051
OPPOSITIONEP2379104
OPPOSITIONUS2010330123
OPPOSITIONUS2011268765
OPPOSITIONUS2013251770
OPPOSITIONWO2010078242
OPPOSITIONWO2017075468
SEARCHUS2010330123
SEARCHUS2013251770

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "BOTOX Cosmetic (onabotulinumtoxinA) for injection, for intramuscular use", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20150801), XP055979262-
OPPOSITION- "BOTOX (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20110801), XP055979259-
OPPOSITION- "Revance Appoints Mark A. Prygocki to Its Board of Directors - Revance Therapeutics, Inc.", Press Release, (20140512), URL: https://investors.revance.com/news-releases/news-release-details/revance-appoints-mark-prygocki-its-board-directors, XP055979264-
OPPOSITION- "Revance Reports Positive 6-Month Duration in BELMONT Study - Revance Therapeutics, Inc.", Press Release, (20151029), URL: https://investors.revance.com/news-releases/news-release-details/revance-reports-positive-6-month-duration-belmont-study, XP055979265-
OPPOSITION- Walker T J, Dayan S H, "Comparison and overview of currently available neurotoxins.", The Journal of Clinical and Aesthetic Dermatology, USA , (20140201), vol. 7, no. 2, ISSN 1941-2789, pages 31 - 39, XP055243263-
OPPOSITION- Garcia-Murray Enrique, Velasco Villasenor María Luisa, Acevedo Berenice, Luna Silvia, Lee Jane, Waugh Jacob M., Hornfeldt Carl S., "Safety and Efficacy of RT002, an Injectable Botulinum Toxin Type A, for Treating Glabellar Lines : Results of a Phase 1/2, Open-Label, Sequential Dose-Escalation Study", DERMATOLOGIC SURGERY, NEW YORK, US , (20150101), vol. 41, no. Supplement 1, doi:10.1097/DSS.0000000000000276, ISSN 1076-0512, pages S47 - S55, XP055979250
OPPOSITION- Car Halina, Bogucki Andrzej, Bonikowski Marcin, Dec-Ćwiek Małgorzata, Drużdż Artur, Koziorowski Dariusz, Rudzińska-Bar Monika, Sarzyńska-Długosz Iwona, Sławek Jarosław, "Botulinum toxin type-A preparations are not the same medications — basic science (Part 1)", NEUROLOGIA I NEUROCHIRURGIA POLSKA, PL , vol. 55, no. 2, doi:10.5603/PJNNS.a2021.0027, ISSN 0028-3843, pages 133 - 140, XP055979238

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents